Share your thoughts on our News & Insights section. Complete our survey to help us improve.

Share research

Fevertree: partners with Molson Coors, 2024 results as expected

Fevertree has teamed up with Molson Coors to help drive its next leg of growth in the US.
Fevertree - US market fuels sales growth

No recommendation - No news or research item is a personal recommendation to deal. All investments can fall as well as rise in value so you could get back less than you invest.

Prices delayed by at least 15 minutes

Fevertree has announced a strategic partnership with global beverage company, Molson Coors, to help drive growth in the US. Molson Coors is set to buy an 8.5% stake in Fevertree for £71mn, which it will return to shareholders in the form of share buybacks, beginning in February 2025.

Fevertree’s also seen full-year revenue rise by 2% to £368mn, ignoring the impact of exchange rates. This was driven by double-digit growth in the US and the Rest of the World, which helped to offset declines in the UK.

The group expects a “strong uplift” in underlying cash profit (EBITDA) when it reports last year’s results. Market expectations currently sit at around £50.8mn.

In 2025, revenue is expected to grow at a low single-digit rate, while increased marketing spend in the US will have a short-term impact on cash profits. In 2026, revenue and cash profits are both expected to grow at double-digit rates.

The shares rose 15.3% in early trading.

Our view

HL view to follow.

Fevertree key facts

All ratios are sourced from Refinitiv, based on previous day’s closing values. Please remember yields are variable and not a reliable indicator of future income. Keep in mind key figures shouldn’t be looked at on their own – it’s important to understand the big picture.

This article is original Hargreaves Lansdown content, published by Hargreaves Lansdown. It was correct as at the date of publication, and our views may have changed since then. Unless otherwise stated estimates, including prospective yields, are a consensus of analyst forecasts provided by Refinitiv. These estimates are not a reliable indicator of future performance. Yields are variable and not guaranteed. Investments rise and fall in value so investors could make a loss.

This article is not advice or a recommendation to buy, sell or hold any investment.No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment.This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication.Non - independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place(including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing.Please see our full non - independent research disclosure for more information.
Latest from Share research
Weekly Newsletter
Sign up for Share Insight. Get our Share research team’s key takeaways from the week’s news and articles direct to your inbox every Friday.
Written by
Aarin Chiekrie
Aarin Chiekrie
Equity Analyst

Aarin is a member of the Equity Research team. Alongside our other analysts, he provides regular research and analysis on individual companies and wider sectors. Having a keen interest in global economics, he knows how macro-events can impact individual companies.

Our content review process
The aim of Hargreaves Lansdown's financial content review process is to ensure accuracy, clarity, and comprehensiveness of all published materials
Article history
Published: 30th January 2025